Emyria launches drug development program focused on mental health based on analysis of its Real-World Evidence.

Emyria’s Managing Director, Dr Michael Winlo, said: “We’re very enthusiastic about the launch of our own evidence-based drug development program after an extensive review of the IP landscape, published literature and, of course, our own clinical evidence.”

Read full announcement here